Ceforanide compared with cefazolin in skin and soft tissue infections.

Abstract

The response of serious skin and skin structure infections to ceforanide 1 gm every twelve hours or cefazolin 1 gm every eight hours was evaluated in ninety-six patients hospitalized for treatment. Most of the patients had decubitus ulcers; predominant pathogens were Staphylococcus aureus, Escherichia coli, and Proteus mirabilis. Ceforanide produced a satisfactory clinical response in 89 percent (forty-eight of fifty-four) of the patients evaluated and eradicated 90 percent (seventy-four of eighty-two) of the pathogens. Although the clinical response of forty-two cefazolin-treated patients was similar (satisfactory response in 86 percent, thirty-six patients), only 81 percent (forty-eight of fifty-nine) of the pathogens were eradicated. Both ceforanide and cefazolin were very well tolerated systemically and locally.

• Authors: L C Parish, J A Witkowski
• Journal: Cutis (Cutis) Vol. 33 Issue 3 Pg. 313-5, 319 (Mar 1984) ISSN: 0011-4162 [Print] United States
• PMID: 6373165 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Cefamandole
• ceforanide
• Cefazolin

Topics

• Adult
• Aged
• Bacterial Infections (complications, drug therapy)
• Cefamandole (administration & dosage, analogs & derivatives, therapeutic use)
• Cefazolin (administration & dosage, therapeutic use)
• Clinical Trials as Topic
• Female
• Humans
• Male
• Middle Aged
• Pressure Ulcer (drug therapy, etiology)
• Skin Diseases, Infectious (drug therapy, etiology)